Yang Fu-Chi, Lin Chun-Chieh, Hsueh Chun-Jen, Lee Jiunn-Tay, Hsu Chang-Hung, Lee Kwo-Whei, Peng Giia-Sheun
Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Ann Vasc Surg. 2010 Nov;24(8):1117-24. doi: 10.1016/j.avsg.2010.07.003.
Local intra-arterial thrombolysis (LIT) has been previously suggested as an effective therapy for acute ischemic stroke. In this study, we describe our experience of using LIT for the treatment of Taiwanese patients with ischemic stroke at different vascular locations, before and after Alteplase was approved as a first-line treatment in Taiwan. The criteria required for the initiation of LIT have become more stringent after the approval of Alteplase (AA).
A retrospective analysis of medical records was conducted for 20 ischemic stroke patients treated with LIT; including 10 patients treated before and 10 patients treated after AA (we did not treat any of the patients in this study with AA). Urokinase was used for LIT treatment. Outcome measures included patient demographics, clinical characteristics, and clinical outcomes before and after LIT. Clinical outcomes were evaluated using four different stroke scales.
The median National Institutes of Health stroke scale score (NIHSS) before treatment was reported to be 19.2 (range: 8-30). After AA, only one patient who had an occluded internal carotid artery (ICA) was treated with LIT. Among the 20 patients, 11 (55%) (five before AA and six after AA) reported having favorable or good clinical outcomes within 3 months of treatment, whereas five reported having poor outcomes (three before AA and two after AA), and the rest four patients died following treatment (two before AA and two after AA). Arterial recanalization was reported as complete in 10 patients (50%; seven middle cerebral artery [MCA] and three basilar artery; six before AA and four after AA), as incomplete in four patients (20%; one MCA and three basilar artery; one before AA and three after AA), and it failed in the remaining six patients (30%; two MCA and four ICA; three before AA and three after AA). Five patients (one MCA and four ICA) in whom recanalization had failed reported having poor outcomes, including one ICA patient who subsequently succumbed to the illness. Intracranial hemorrhagic and intraventricular hemorrhage transformation occurred in three and two patients, respectively. A case of intraventricular hemorrhage transformation after AA was also reported.
On the basis of our experience, we found that LIT was of limited value in patients with ICA occlusion before AA approval. After AA, the outcomes in acute stroke patients, who were receiving urokinase therapy and who were carefully selected on the basis of the site of occlusion, were improved.
局部动脉内溶栓(LIT)此前已被认为是治疗急性缺血性卒中的有效疗法。在本研究中,我们描述了在台湾阿替普酶被批准作为一线治疗药物之前和之后,使用LIT治疗不同血管部位缺血性卒中台湾患者的经验。阿替普酶(AA)获批后,启动LIT所需的标准变得更加严格。
对20例接受LIT治疗的缺血性卒中患者的病历进行回顾性分析;包括AA获批前治疗的10例患者和获批后治疗的10例患者(本研究中我们未使用AA治疗任何患者)。尿激酶用于LIT治疗。结果指标包括患者人口统计学特征、临床特征以及LIT治疗前后的临床结局。使用四种不同的卒中量表评估临床结局。
据报告,治疗前美国国立卫生研究院卒中量表(NIHSS)评分中位数为19.2(范围:8 - 30)。AA获批后,仅1例颈内动脉(ICA)闭塞患者接受了LIT治疗。在这20例患者中,11例(55%)(AA获批前5例,获批后6例)在治疗后3个月内报告有良好或较好的临床结局,而5例报告结局较差(AA获批前3例,获批后2例),其余4例患者治疗后死亡(AA获批前2例,获批后2例)。据报告,10例患者(50%;7例大脑中动脉[MCA]和3例基底动脉;AA获批前6例,获批后4例)动脉再通完全,4例患者(20%;1例MCA和3例基底动脉;AA获批前1例,获批后3例)动脉再通不完全,其余6例患者(30%;2例MCA和4例ICA;AA获批前3例,获批后3例)动脉再通失败。5例(1例MCA和4例ICA)再通失败的患者报告结局较差,其中1例ICA患者随后因病死亡。分别有3例和2例患者发生颅内出血和脑室内出血转化。还报告了1例AA获批后发生脑室内出血转化的病例。
根据我们的经验,我们发现AA获批前,LIT对ICA闭塞患者的价值有限。AA获批后,接受尿激酶治疗且根据闭塞部位精心挑选的急性卒中患者的结局有所改善。